Skip to content

AMOXICILLIN VERSUS AMOXICILLIN-CLAVULANATE VERSUS PLACEBO IN ACUTE OTITIS MEDIA IN CHILDREN – A PARALLEL-GROUP TRIPLE-BLINDED RANDOMIZED CONTROLLED SUPERIORITY TRIAL

Status
Not yet recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524259-30-00
Enrollment
219
Registered
2026-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute otitis media

Brief summary

The primary outcome is condition of the child, measured daily in days 1-7 and at days 10 and 14 with AOM-SOS score version 6.0. The treatment effectiveness measured as risk ratios and generalized estimation equations (GEE) are used to convert the daily mean comparisons into relative effect estimates

Detailed description

Secondary outcomes are proportions of children - needing rescue antibiotics - with no improvement of overall condition by the first scheduled control visit (day 2-4) - with no improvement of otoscopic signs (7-9 day visit) - with middle ear effusion at days 2, 7 and 14 - with development of contralateral AOM during the treatment - with spontaneous perforation of the tympanic membrane during the treatment - with side effects (for ex. diarrhea, rash)

Interventions

DRUGSyrsSpend SF pH 4
DRUGAmorion 100 mg/ml jauhe oraalisuspensiota varten

Sponsors

Pohjois-Savon hyvinvointialue
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
The primary outcome is condition of the child, measured daily in days 1-7 and at days 10 and 14 with AOM-SOS score version 6.0. The treatment effectiveness measured as risk ratios and generalized estimation equations (GEE) are used to convert the daily mean comparisons into relative effect estimates

Secondary

MeasureTime frame
Secondary outcomes are proportions of children - needing rescue antibiotics - with no improvement of overall condition by the first scheduled control visit (day 2-4) - with no improvement of otoscopic signs (7-9 day visit) - with middle ear effusion at days 2, 7 and 14 - with development of contralateral AOM during the treatment - with spontaneous perforation of the tympanic membrane during the treatment - with side effects (for ex. diarrhea, rash)

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 18, 2026